Clinical Trial

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Trial Details
NCT Number NCT07196579
Lead Sponsor TCRx Therapeutics Co.Ltd
Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions Advanced Solid Cancer
Enrollment 30 participants
Start Date 2025-10-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-29